Rising incidence of investment in biomarkers for drug development is the major factor influencing market growth.
Market Size – USD 18.23 billion in 2018, Market Growth - CAGR of 4.6%, Market Trends –Rise in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies.
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- The Alzheimer’s Therapeutics Market is expected to reach USD 12.43 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the growing pipeline drug development, investment in biomarkers for drug development which are expected to further accelerate the market growth globally. Based on statistics, increase in advanced diagnostics for early detection, along with more specific drug development, and emerging innovative diagnostics technologies are also some of the factors that are also helping to grow the size of the global market.
Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/1364
Alzheimer's disease (AD) is the most usual cause of dementia worldwide. The study of this disease is multifactorial, and pathophysiology is also complicated. According to several types of research, an exponential rise in the number of cases of AD, highlighting the need for developing an effective treatment. AD also imposes a tremendous emotional and financial trouble to the patient's family and society. The disease has been studied for more than a century, but memantine and acetylcholinesterase inhibitors are the only drugs currently recommended for its management. These drugs provide significant improvement alone but do less to change the disease process. The significant penetration into the molecular and cellular pathomechanism in AD over the previous few decades has given us considerable progress in the understanding of the disease. Several novel strategies that seek to revise the disease process have been developed. The notable developments in this direction are the tau-based and amyloid therapeutics, which could hold the key to treatment of AD shortly.
North America market for Alzheimer’s Therapeutics accounts for the largest share of 29.30% in 2018. Due to the presence of advanced healthcare facilities and infrastructure in developed countries, such as the U.S. Moreover, the high buying power for expensive drugs and compensation policies are the drivers projected to promote the market demand.
Further key findings from the report suggest
- Alzheimer’s is a kind of dementia, which affects thinking, behavior, and memory of the patient. The progression of the disease is moderate, and it diminishes neurons associated with the learning part of the cerebrum. It is the most common and the most significant form of dementia (more than 60%), which can be observed in people of age between 65 and over.
- Many researches are being conducted to promote treatment concentrated on the role of beta-amyloid in Alzheimer’s disease. The artificial joints are designed to replicate the movement of a typical, healthy joint.
- Cholinesterase inhibitors therapeutics accounts for the largest share of 38.85% in 2018. It can also improve neuropsychiatric symptoms, such as depression or agitation.
- Generally prescribed cholinesterase inhibitors are galantamine (Razadyne), donepezil (Aricept), and rivastigmine (Exelon).
- CT scans often can reveal specific changes that are characteristic of Alzheimer's disease in its succeeding stages. These changes include widened indentations in the tissues, a reduction in the size of the brain (atrophy), and expansion of the fluid-filled chambers called cerebral ventricles.
- CT scan diagnostic type is expected to reach USD 4.95 billion by 2026. CT (computed tomography) scan is a procedure in which various X-rays of the body are examined from several angles in a short period.
- CT imaging generates the images by estimating how quickly the body and organs receive the X-rays.
To identify the key trends in the industry, click on the link below:
https://www.reportsanddata.com/report-detail/alzheimers-therapeutics-market
- The pipeline drugs sector accounts for a market share of 31.15% in 2018. The presence and advancement of pipeline drugs, such as LMTX by TauRx Pharmaceuticals Ltd., are anticipated to have a substantial positive impact on the growth of this industry.
- This drug is under Phase 3 clinical trial currently to assess its safety and efficacy in the therapy of mild-to-moderate Alzheimer’s disease.
- The result of the clinical trial is supposed to be announced in 2016. Other pipeline drugs include verubecestat by Merck. & Co., Inc.; crenezumab by AC Immune SA; and idalopirdine (Lu AE58054) by Lundbeck A/S, which are in Phase 3 of a clinical trial and are expected to be launched over the next 6 years.
- Many organizations included in this activity are Alzheimer’s Association, the National Institute of Health (NIH), and the Florida Department of Health. The NIH contributed around USD 589 million on research projects for AD in 2015.
- Recently, a new proposal known as Alzheimer’s Combination Therapy Opportunities was launched in collaboration with Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Society UK. This proposal is expected to provide growth opportunities for the market.
- The proposal involves a combination of repurposed or repositioned drugs that have the ability to slow down the progression of AD.
- Key participants include Eli Lilly and Company, Daiichi Sankyo, Hoffmann-La Roche Ltd, Pfizer, Inc., Eisai Co., Ltd., Novartis AG, H. Lundbeck A/S, TauRx Therapeutics Ltd, Forest Laboratories, Inc., AC Immun, Johnson & Johnson, TauRx Pharmaceuticals Ltd, VTV Therapeutics
- APAC is anticipated to grow at a CAGR of 6.2% during the forecast period. The region is forecasted to witness the accelerated growth over the forecast period owing to the increasing disposable income level.
Order Now: https://www.reportsanddata.com/checkout-form/1364
Segments covered in the report:
For the purpose of this study, Reports and Data have segmented the global Alzheimer’s Therapeutics Market on the basis of Therapeutics, End-User, Diagnostics Type and Region:
Therapeutics Outlook (Revenue, USD Million; 2016-2026)
- Cholinesterase inhibitors
- Pipeline Drugs
- NMDA receptor antagonist
End User Outlook (Revenue, USD Million; 2016-2026)
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
Diagnostics Type Outlook (Revenue, USD Million; 2016-2026)
- Computed tomography (CT) scan
- Magnetic resonance imaging (MRI)
- Lumbar puncture test
- Electroencephalography (EEG)
- Others
Regional Outlook (Volume, Kilo Tons; Revenue, USD Billion; 2018-2026)
- North America
○ U.S. - Europe
○ UK
○ France - Asia Pacific
○ China
○ India
○ Japan - MEA
- Latin America
○ Brazil
Browse more reports of Pharmaceutical category at: https://www.reportsanddata.com/report/category/pharmaceutical
About Reports and Data
Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.
Contact Us:
John Watson
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-800-819-3052
E-mail: sales@reportsanddata.com